NovaRx initiates Phase III lung cancer trial

The first patient enrolled in the study was treated by Lyudmila Bazhenova, the trial’s principal investigator at the University of California, San Diego School of Medicine.

The study is designated as the Stop trial because of its expected endpoints: survival; tumor-free, overall; and progression-free. It is an international, multicenter, randomized, double-blind study involving up to 700 individuals with advanced stage non-small cell lung cancer (NSCLC), and will be conducted at approximately 90 clinical sites in the US, Canada, India and Europe.

Dr Bazhenova said: “This is a very promising approach to cancer treatment, and results reported so far are beyond anyone’s expectations. I am very excited to be a part of this confirmatory effort, and to be able to offer this unique treatment option to my patients.

“Traditional chemotherapy for stage IV NSCLC still yields disappointing results, and my hope is that this trial will improve the natural history of the disease.”